Tirzepatide may be favored when: Maximum weight loss is the primary goal and cost/insurance isn't a barrier A patient has type 2 diabetes and would benefit from tirzepatide's strong glycemic effects A patient didn't achieve adequate results on semaglutide Semaglutide may be favored when: Cost or insurance coverage strongly favors semaglutide A patient's prescriber has a longer track record of clinical experience with the drug (semaglutide has been used clinically for weight loss for longer) A patient tolerates GLP-1-only therapy well and doesn't need the added GIP effect Neither may be appropriate when: A patient has a personal or family history of medullary thyroid carcinoma or MEN2 syndrome A patient is pregnant, breastfeeding, or planning pregnancy soon A patient has a history of pancreatitis or certain GI conditions, without further evaluation A doctor or obesity-medicine specialist will weigh medical history, current medications, lab work, weight-loss goals, and cost before recommending either drug and will monitor treatment over time, adjusting the plan as needed
Patients seeking snack alternatives to popcorn while on semaglutide should focus on options that provide nutritional value without triggering gastrointestinal discomfort
Wegovy : Both contain semaglutide, but Ozempic is FDA-approved for type 2 diabetes while Wegovy is approved specifically for weight loss
Complment alimentaire rtention deau et jambes lourdes Les jambes lourdes sont souvent associes une mauvaise circulation des fluides et une accumulation deau dans les tissus
Dong H, He L, Sun Q, et al
An Indian study on HIFU for face and neck tightening reported improved jawline contour, brow lifting and reduced laxity with minimal downtime
